Before SG, the improvers of fatty liver (FL-I group) demonstrated significantly lower body weight (94.4 ± 9.7 vs. 121.3 ± 19.7 kg, p < 0.05), lower waist circumferences (104.7 ± 6.1 vs. 122.9 ± 12.0 kg/m2, p < 0.05), lower FGF 19 (48.7 ± 18.0 vs. 101.2 ± 42.4%, p < 0.05) than the non-improvers of fatty liver (FL-non-I group). This evidence concerns the gene FGF19 and Hepatic steatosis.